- 23 April 2024
This interactive discussion will cover topics such as:
- Identify important considerations for ensuring compatibility of IMP with common infusion materials and how they impact delivery of drug to the patient
- Identify key stakeholders (e.g. CMC, Clinical, CROs, CMOs) that are involved in the process and how they may be leveraged to support the process.
- Discuss how to develop a plan to ensure availability and continuity of compatible ancillaries across all regions the trials will be conducted in
- Poll group and review pros and cons of different organizational approaches to management and delivery of ancillary supplies